Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Halozyme Therapeutics Inc. (HALO:NASDAQ), powered by AI.
Halozyme Therapeutics Inc. is currently trading at $69.64. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Halozyme Therapeutics Inc. on Alpha Lenz.
Halozyme Therapeutics Inc.'s P/E ratio is 26.3.
“Halozyme Therapeutics Inc. trades at a P/E of 26.3 (premium valuation) with strong ROE of 153.6%. 3Y revenue CAGR of 28.4% highlights clear growth momentum.”
Ask for details →Halozyme Therapeutics Inc. is a biopharmaceutical company that specializes in developing and commercializing treatments focused on enhanced subcutaneous drug delivery. The company's proprietary technology, ENHANZE, aims to improve the efficacy and convenience of existing therapies by facilitating faster drug absorption and reducing the need for intravenous administration. Halozyme partners with major pharmaceutical companies to integrate its technology with a variety of treatments, significantly impacting the oncology, immunology, and genetic disorder sectors. This collaboration model helps expand the reach of its technology across multiple therapeutic applications. Based in San Diego, California, Halozyme is noted for its innovative approach to drug delivery, contributing to the broader pharmaceutical industry's efforts to improve patient experiences and optimize medical outcomes. As a significant player in the biopharmaceutical landscape, Halozyme's advancements continue to drive interest and growth within the market, underscoring the vital role of drug delivery technology in modern medicine.
“Halozyme Therapeutics Inc. trades at a P/E of 26.3 (premium valuation) with strong ROE of 153.6%. 3Y revenue CAGR of 28.4% highlights clear growth momentum.”
Ask for details →Halozyme Therapeutics Inc. (ticker: HALO) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 350 employees. Market cap is $8.3B.
The current price is $69.64 with a P/E ratio of 26.34x and P/B of 170.97x.
ROE is 153.59% and operating margin is 57.47%. Annual revenue is $1.4B.